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Background: Billions of cells undergo apoptosis each day in the average normal adult. The ability to readily assess
the degree of apoptosis in human diseases is hampered by the lack of sensitive and speciﬁc serum biomarkers of
apoptosis. Fortilin is a novel prosurvival molecule that protects cells against various noxious stimuli. While
fortilin is secreted into the extracellular space under certain conditions, the relationship between the serum con-
centration of fortilin and the presence and extent of apoptosis in vivo remains unknown.
Methods & results:Using a newly developed fortilin ELISA system, we show here that fortilin exists in the normal
human andmouse circulation. We further demonstrate that fortilin serum levels are signiﬁcantly elevated in pa-
tients with solid cancer, in response to anti-cancer chemo- or radiation therapy. The elevation of fortilin serum
levels is more robust and sensitive than that of such previously-reported serum biomarkers of apoptosis as
fragmented cytokeratin-18, cytochrome c, and nucleosomal DNA. In addition, targeted apoptotic liver damage in-
duced by Jo2 anti-Fas (CD95) antibody consistently and signiﬁcantly increased serum fortilin levels in C57BL/6J
mice. Finally, when challenged by anti-human-Fas IgM antibody, Jurkat leukemic T cells apoptosed and released
fortilin into the medium before plasma membrane integrity was compromised.
Conclusions: Taken together, these data suggest that serum fortilin levels reﬂect the degree and extent of apopto-
sis occurring in vivo.
General signiﬁcance: Fortilin is a viable serum biomarker of in vivo apoptosis and can be utilized to noninvasively
assess the status of in vivo apoptosis in humans.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Approximately 50 to 70 billion cells undergo apoptosis each day in the
average normal adult [1]. Serumbiomarkers of apoptosis –molecules that
can be readily and objectively measured as indicators of normally and
pathologically occurring apoptosis at tissue and organ levels – would
allow clinicians to easily monitor the status of apoptosis associated with
the diseases and conditions they treat—such as apoptosis-induced skele-
tal muscle atrophy resulting from cancer (cachexia), aging (sarcopenia)
[2], starvation, denervation, disuse, and inﬂammation [3]. Cancer cells
undergo apoptosis at a higher rate than do normal cells and massively
apoptose in response to radiation therapy and chemotherapy [4]. Serumpartment of Internal Medicine,
d, Suite JSA5.106G, Galveston,
1777.
. This is an open access article underbiomarkers of apoptosis could thus allow clinicians to screen patients
for certain cancers or to monitor the response of patients with cancer to
anti-cancer chemo- or radiation therapy [5].
Thus far, three serum biomarkers of apoptosis have been reported in
the literature including the fragmented cytokeratin-18 (fCK18, detectable
by the M30 antibody), nucleosomally-cleaved genomic DNA (n-DNA),
and cytochrome c (Cyt C) [5]—each with notable limitations to their util-
ity. The utility of fCK18 is limited to apoptosis occurring in cells of epithe-
lial origin [6]. The utility of circulating n-DNA is diminished because it can
be rapidly degraded by serum DNases [7]. Cyt C is reportedly released
from both apoptotic [8] and necrotic cells [9], depending on the extent
of cellular damage, thus limiting its speciﬁcity. Further, these candidate
serum apoptosis biomarkers have not been extensively characterized or
validated at clinical, whole animal, and cellular levels.
Fortilin, also known as translationally controlled tumor protein
(TCTP) and IgE-dependent histamine releasing factor (HRF), is a 172-
amino acid nuclear-cytosolic shuttle protein that was originally clonedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tumor cells [10]. Amultifunctional protein implicated in various cellular
functions [11–16], fortilin possesses potent anti-apoptotic activity [12,
17–22]. It binds the sequence-speciﬁc DNA binding domain of p53
and prevents p53 from transcriptionally activating the proapoptotic
gene Bax [23]. Fortilin also binds to and stabilizes MCL1 [22], a
macrophage survival factor [24,25]. In addition to being intracellularly
located, fortilin can be trafﬁcked into exosomes – small secretory
vesicles – and eventually be released into the extracellular space in an
ER/Golgi-independent fashion [15]. However, it remains unknown if
fortilin actually circulates in the blood of normal humans and animals.
Further, it is not known if serum fortilin levels change in response to
various pathophysiological conditions, including apoptosis occurring
in body tissues.
Since it is a potent anti-apoptotic molecule that can be secreted into
the extracellular space, we hypothesized that fortilin could be a viable
serum apoptosis biomarker. Here, we report for the ﬁrst time that
fortilin is present in the blood of healthy humans and mice. We also
show that anti-cancer chemo- or radiation therapy causes serum fortilin
levels to increase, more robustly, sensitively and speciﬁcally than fCK-
18, Cyt C, or n-DNA in humans. Strikingly, the release of fortilin from
the cell precedes any signs of compromised plasma membrane integri-
ty. We therefore propose that serum fortilin is a sensitive and robust
biomarker of apoptosis occurring in vivo.
2. Materials and methods
2.1. Cell culture and cell lines
The Jurkat cell lines (Clone E6-1) were purchased from American
Type Culture Collection (ATCC, Manassas, VA). All cell lines were
maintained in high-glucose Roswell Park Memorial Institute (RPMI)
medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in
an atmosphere containing 10% CO2.
2.2. Cell-based assay of biomarkers release and plasmamembrane disruption
Jurkat cells were seeded in 18 wells of 6-well plates (5 × 105 cells/
well) in RPMImediumwith 5% FBS. The next day, the cells werewashed
oncewith phosphate buffered saline (PBS) and re-suspended in 1mL of
RPMI medium containing 12.5 ng/mL of anti-human Fas IgM (clone
CH11). At each time point (0, 0.5, 1, 2, 4, and 8 h, N = 3 for each time
point), we harvested 500 μL of cell suspension, centrifuged it at 100 g
for 5 min, transferred the medium to fresh microfuge tubes, and froze
both the media and cell pellets separately at−80 °C until the assays
for LDH, n-DNA, fortilin, Cyt C, and fCK-18, were performed. For 7-
AAD staining, we added 20 μL of 7-AAD solution (BD Pharmingen) to
400 μL of cell suspension and incubated it for 10 min at room tempera-
ture, shielded from light. We counted total and 7-AAD-positive cells
under the ﬂuorescence microscope as described previously [26]. The
integrity of the plasma membrane of the cells with positive 7-AAD
signal is compromised. At least 200 cells were counted and the 7-ADD
index was calculated as (the number of 7-AAD-positive cells) / (the
number of total cells) ∗ 100.
2.3. Mouse model of targeted liver apoptosis
All animal procedures were performed according to a protocol
approved by the UTMB Institutional Animal Care and Use Committee
(IACUC), in accordancewith the National Institutes of Health guidelines
and the “Position of the AmericanHeart Association on ResearchAnimal
Use.” We induced apoptosis in the liver of C57BL/6J male mice
(12 weeks of age) by intraperitoneal administration of the Jo2 anti-Fas
antibody (1.25 μg/body weight in gram, resulting in approximately
25 μg of antibody per mouse): PBS was used as a control. Once injected,
the mice became ill within 3 h; half of them were dead within 6 h, asdescribed previously [27]. At 5–9 h after anti-Fas injection, when they
were clinically moribund, the mice were sacriﬁced, their blood collect-
ed, and the organs harvested for further analyses. Jo2 antibody binds
the mouse Fas antigen and induces Fas-mediated apoptosis in the liver
without affecting any other tissues as reported previously [27].
Transmission electron microscopic examination reportedly showed a
lack of phagocytosis of apoptosed cells. Also, there was no gross leakage
of cell contents into the extracellular space observed by the same exam-
ination [27].
2.4. Caspase-3 activity
Caspase-3 assays were performed as we described previously
[28]. In brief, cells were suspended in cell lysis buffer (10 mM Tris,
pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.01% Triton X-100), subjected
to three freeze-thaw cycles, and centrifuged at 14,000 g. Aliquots of
cleared cell lysates were incubated with 2.5 mM rhodamine 110
bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid amide)(Z-
DEVD-R110) substrate (Invitrogen-Molecular Probes, Grand Island,
NY). Caspase-3 activities were determined every 5 min for 90 min
by measuring ﬂuorescence (excitation/emission = 496/520 nm),
using the SpectraMax Plus microplate spectrophotometer (Molecu-
lar Devices, Sunnyvale, CA), and expressed as relative ﬂuorescence
units (RFU).
2.5. TUNEL staining
TUNEL staining was performed as we previously described [23],
using the FragEL™ DNA Fragmentation Detection Kit (EMD Millipore,
Calbiochem, Billerica, MA), according to the manufacturer's instruc-
tions. At least 600 cellswere counted andTUNEL indiceswere calculated
as the number of TUNEL-positive cells divided by the number of total
cells counted and expressed as percentages.
2.6. Lactate dehydrogenase (LDH) activity assay
Serum LDH activity was measured by the LDH Activity Assay Kit
(Sigma-Aldrich, St. Louis, MO; Catalog Number: MAK066) according to
the manufacturer's instructions.
2.7. Serum Cyt C assay
SerumCyt Cwas quantiﬁed by the Human CytochromeCQuantikine
ELISA kit (R&D Systems, Minneapolis, MN; Catalog Number: DCTC0)
according to the manufacturer's instructions.
2.8. Serum alanine transaminase (ALT) assay
Serum ALT was quantiﬁed by the mammalian liver proﬁle rotor and
VETSCAN VS2 (Abaxis, Union City, CA) according to the manufacturer's
instructions.
2.9. DNA fragmentation assay
The Cell Death Detection ELISA PLUS kit (Roche, Indianapolis, IN,
Catalog Number: 11774425001) was used according to the manufac-
turer's instruction and modiﬁcations described previously [23]. We
added 20 μL of serum from a patient into a well of a streptavidin-
coated 96-well plate, in triplicate. We then added 80 μL of incubation
buffer (PBS supplemented with 1% BSA, 0.5% Tween 20 and 1 mM
EDTA), containing peroxidase-conjugated mouse anti-DNA antibody
(MCA-33) and mouse biotinylated anti-histone antibody (H11-4) to
the wells and incubated the plate for 2 h at room temperature on a
shaker. The plate was then washed three (3) times with incubation
buffer before we added 100 μL of 2,2′-Azinobis [3-ethylbenzothiazo-
line-6-sulfonic acid]-diammonium salt (ATBS) solution to each well,
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development was sufﬁcient for reading (2–10 min), and added 100 μL
of the ATBS Stop Solution.
2.10. Fragmented cytokeratin-18 (fCK-18) determination
Cytokeratin-18 (CK-18), a 48-kDa, 423 amino-acid polypeptide, is a
major component of intermediate ﬁlaments of cells of epithelial origin.
M30 is a monoclonal antibody produced by immunizing Balb/c mice
with two puriﬁed CK18 fragments [29]. The epitope of M30 is the 387–
396th amino acids of CK18 (EDFNLGDALD), representing the COOH-
terminal amino acid residues of the intermediate 19-kDa fragment gener-
ated by caspases-3 and -7.M30 does not recognize the intact CK18where
it has not been cleavedbetween396th asparatic acid (D) and397th serine
(S) by caspases [29], thus making M30 reactivity speciﬁc for apoptosis.
The exact molecular mechanism bywhich CK-18 is released from epithe-
lial cells undergoing apoptosis remains unknown [30]. Quantiﬁcation of
the caspase-generated neoepitope of CK-18 in serum samples was
performed using the M30-Apoptosense ELISA kit (Peviva, Bromma,
Sweden) as described previously and according to the manufacturer's
instructions, in triplicates. The standard curves were generated by using
synthetic immunogenic peptides provided with the kit.
2.11. ELISA to quantify the serum concentration of mouse and human
fortilin
A polystyrene 96-well plate (BD Falcon, Bedford, MA) was coated
with 50 μL of capture anti-fortilin antibody (Abnova, Taipei City,
Taiwan; Clone 2C4; Catalog Number: H00007178-M03) diluted at
1 μg/mL in PBS and incubated at 4 °C overnight. After the wells were
washed ﬁve (5) times with wash buffer (PBS with 0.1% Tween 20),
they were blocked with 100 μL of blocking buffer (PBS with 1% BSA)
for 1 h at room temperature. The wells were then washed ﬁve
(5) times with wash buffer. 100 μL each of the samples, dissolved at
an appropriate concentration in dilution buffer (PBS with 0.1% BSA),
was then added to each well and incubated at 37 °C for 3 h. The wells
were then washed ﬁve (5) times with wash buffer. 100 μL of biotinylat-
ed anti-fortilin detection antibody (Abnova; Clone 2A3; Catalog Num-
ber: H00007178-M06) diluted at 1 μg/mL in dilution buffer was added
to each well, and the plate was incubated at 37 °C for 2 h. After wells
were washed ﬁve (5) times with wash buffer, 100 μL of avidin-HRP
(eBioscience, San Diego, CA, diluted at 1:500 in dilution buffer) was
added to each well. The wells were then washed ﬁve (5) times with
wash buffer. To detect bound antibody, 100 μL of Strep™ Ultra TMB-
ELISA (Thermo Fisher Scientiﬁc, Waltham, MA) was added to each
well and the platewas incubated at room temperature for 30min before
50 μL of 2 M sulfuric acid was added to stop the reaction. The signal was
readwith a plate reader at 450nm. The Coefﬁcient of Variation (CV)was
determined as %CV = SD/mean × 100 using the data obtained from
normal human subjects. The limit of detection was deﬁned as the
fortilin concentration at which the current ELISA system gives a statisti-
cally signiﬁcant value above that of the zero analyte (dilution buffer
alone) at a 99% conﬁdence level, i.e., the means of the quadruplicates
of the zero analyte and those of fortilin at the detection-limit concentra-
tion must differ by three SDs.
2.12. Collection of human serum samples
Human sera were collected under protocols approved by the UTMB
Internal Review Board. Detailed information on the samples from the
patients undergoing anti-cancer therapy is shown in Table 1. Written
informed consentwas received fromparticipants prior to sample collec-
tion. The samples were frozen at −80 °C until the described assays
were performed. All samples were free of any identifying information
at the time of assay.2.13. Statistical analysis
The degree of spread of the data was expressed as the standard
deviation (± SD). P b 0.05 was considered to be statistically signiﬁcant.
The Student's t-test was employed for comparing the means of two
groups.
3. Results
3.1. Fortilin ELISA development
There have been no robust quantitative assays reported for fortilin.
To evaluate fortilin as a serum apoptosis biomarker, we ﬁrst developed
a sandwich enzyme-linked immunosorbent assay (ELISA) of fortilin
using two distinct anti-fortilin monoclonal antibodies and avidin-
based signal ampliﬁcation as described in detail in the Materials and
methods section (Fig. 1A). The detection limit of the developed ELISA
was 0.4 ng/mL (Fig. 1B) with an 8.6% coefﬁcient of variation (CV).
3.2. Fortilin circulates in the blood of normal humans and mice
To test the hypothesis that fortilin circulates in the blood, the sera
from 12-week-old C57BL/6J male and female mice (n= 30) were sub-
jected to the above fortilin ELISA assay, showing average mouse serum
fortilin levels of 48.16± 12.96 ng/mL with no signiﬁcant difference be-
tween male and female mice (males vs. females = 49.22 ± 14.48 vs.
47.10 ± 11.66 ng/mL, n = 15 each, P = 0.663; Fig. S1). The samples
were distributed normally (Anderson–Darling [AD] normality test, AD
value = 0.292, P= 0.581; Fig. 1C) with the 5 and 95 percentile values
of 28.84 and 69.48 ng/mL (Fig. 1D). We then used the same ELISA
assay to examine the sera from 63 patients presenting to clinic for rou-
tine examination. Their average fortilin serum concentration was
75.57 ± 45.79 ng/mL with no signiﬁcant difference between male and
female human subjects (males vs. females = 77.6 ± 49.9 vs. 74.1 ±
43.3 ng/mL, n = 26 and 37, respectively, P = 0.77; Fig. S2A). There
was also no statistically signiﬁcant correlation between age and fortilin
levels (Fig. S2B). Unlike themouse samples, the human samples did not
distribute normally (Anderson–Darling [AD] normality test, P b 0.005;
Fig. 1E). The data best ﬁts the gamma distribution with the lowest AD
value (0.182, P N 0.250), with the 5 and 95 percentile values of 18.68
and 163.546 ng/mL (Fig. 1 F). Taken together, these data suggest that
fortilin circulates in the blood of both normal humans and mice.
3.3. Serum fortilin levels are signiﬁcantly elevated after anti-cancer chemo-
and radiation therapy
Fortilin has been shown to protect cells against apoptosis and to be
released into the extracellular space via secretory exosomes [15]. To
test the hypothesis that serum fortilin levels reﬂect apoptosis occurring
at the tissue level, we quantiﬁed serum fortilin concentrations in pre-
and post-treatment sera of patients with solid malignancies (cervical/
neck cancers and squamous cell carcinoma [SCC]) who were undergo-
ing anti-cancer chemo- or radiation therapy (“anti-cancer therapy”
hereafter), as both anti-cancer drugs and ionizing radiation trigger
apoptosis in cancer tissue (Table 1). The mean pre-treatment serum
fortilin levels in these cancer patients were 29.0 ± 15.5 ng/mL. After
chemotherapy, however, the mean serum fortilin levels increased 2.40
fold to 69.6 ± 47.2 ng/mL (P b 0.001, Paired Student's t-test; Fig. 2). Of
18 samples tested, 14 (77.8%) showed a statistically signiﬁcant increase
in fortilin levels after anti-cancer therapywhile two (11.1%)were signif-
icantly decreased (Fig. 2). These data indicate that serum fortilin levels
generally increase in response to anti-cancer therapy.
We also determined the lactate dehydrogenase (LDH) levels in
these samples as these levels may reﬂect anti-cancer-therapy-
induced tissue necrosis [8]. The mean pre-treatment serum LDH level
was 33.36 ± 12.54 mU/mL, while the mean post-treatment serum
Table 1
Summary of patients undergoing anti-cancer chemotherapy.
Patient
number
Age Sex Diagnosis Therapy Post-treatment
sampling
LDH Fortilin Established apoptosis
biomarkers
Type Location Recurrent Stage Radiation
therapy
Chemotherapy (Days after the
last therapy)
Anyone Cyt
C
n-
DNA
CK-
18
1 49 F SCC Cervical Yes IIIB NO Cisplatin 26 ↑ ↑↑ ↑ ↑
2 35 F SCC Cervical Yes IIIB NO Cisplatin 11 ↑
3 40 F SCC Cervical Yes IIIB NO Cisplatin 50 ↑ ↑↑ ↑ ↑
4 48 F SCC Cervical No IIIB YES Cisplatin 16 ↑ ↑
6 49 F SCC Cervical No IIIB YES Cisplatin 3 ↑
7 53 F SCC Cervical No IIB YES Cisplatin 7 ↑ ↑ ↑
8 47 F SCC Cervical No IV YES Cisplatin 1 ↑
9 43 F SCC Cervical No IIIB YES NO 7 ↑ ↑ ↑
10 48 M SCC Retromolar
trigone
No T4bN2b YES Cisplatin 20 ↑
11 62 M SCC Hypopharynx No T3N2 YES Cisplatin 44 ↑
12 71 M SCC Larynx &
NSCLC
No T3N2 &
T2N0
YES NO 1 ↑
13 38 M ACC Maxillary
sinus
No NA YES NO 1 ↑
14 51 F SCC Tonsil No T4aN1 YES TPF 54 ↑
15 59 M SCC Retromolar
trigone
No T4BbN2b YES Cisplatin 7 ↑
16 53 F SCC Base of the
tongue
No T4N2 YES NO 1 ↑
17 35 M Mucoepidermoid
carcinoma
Base of the
tongue
No IV YES NO 1 ↑ ↑ ↑
18 67 M SCC Base of the
tongue
No T4bN2b YES Cisplatin 1 ↑ ↑ ↑
19 52 M SCC Tonsil No IVa
(T3N2)
YES Cisplatin 16
Abbreviation: F, female;M,male; SCC, squamous cell cardinoma; ACC, adenocystic carcinoma; NSCLC, non-small-cell lung carcinoma; TPF, docetaxel, cisplatin, 5-ﬂuorouracil; NA, data not
available. Patient #10: a sufﬁcient amount of post-treatment sample available only for fortilin ELISA. Patient #5: excluded from the study as post-treatment sample volume was not suf-
ﬁcient for any assays.
106 P. Sinthujaroen et al. / BBA Clinical 2 (2014) 103–111LDH level was 30.46 ± 11.81 IU/mL (P= 0.38, NS). Out of 17 samples
tested (the patient #10 was excluded as we did not have enough post-
treatment sera remaining for assays), only two (11.8%) had a statisti-
cally signiﬁcant increase in LDH levels after anti-cancer therapy while
four (23.5%) were signiﬁcantly decreased (Fig. 3A). Further, regression
analysis showed no statistically signiﬁcant association between the
fold-change of serum fortilin levels and that of LDH levels after anti-
cancer therapy (P = 0.552, R2 = 2.4%; Fig. 3B). These data suggest
that anti-cancer treatment induced no signiﬁcant degree of tissue
necrosis and that fortilin elevation was not due to the necrotic plasma
membrane damage in cancer cells (Fig. 3A & B).
3.4. Serum fortilin is superior to the other apoptosis biomarkers
To compare serum fortilin levels with the other apoptosis bio-
markers described in the literature, we assayed the same samples for
Cyt C, n-DNA, and fCK-18 levels.
First, we found that themean serum Cyt C levels did not statistically
change (from 0.90 ± 0.26 to 0.83 ± 0.31 ng/μL, paired Student's t-test,
P= 0.19) between before and after anti-cancer therapy. Out of 17 sam-
ples tested, only two (11.7%) showed a statistically signiﬁcant increase
in Cyt C levels after anticancer therapy while two (11.7%) had a statisti-
cally signiﬁcant decrease (Fig. 4A).
Next, we determined serum n-DNA levels before and after anti-
cancer therapy and found that the mean serum n-DNA levels did not
statistically change (from 0.23 ± 0.25 to 0.21 ± 0.38 ng/μL, paired
Student's t-test, P = 0.820). Of 17 samples tested, only 4 (23.5%)
showed a statistically signiﬁcant increase in n-DNA levels after anti-
cancer therapy, while 2 (11.7%) had a statistically signiﬁcant decrease
(Fig. 4B).
Upon assaying serum fCK-18 levels before and after anti-cancer
therapy, we found that the mean serum fCK-18 levels did not statis-
tically change (from 139.78 ± 98.1 to 148.4 ± 100.3 U/L, paired
Student's t-test, P = 0.197). Of 17 samples tested, only 2 (11.7%)showed a statistically signiﬁcant increase in fCK-18 levels after
anti-cancer therapy while one (5.8%) had a statistically signiﬁcant
decrease (Fig. 4C).
Serum fortilin levels were signiﬁcantly elevated in all patients who
had at least one of three established biomarkers of apoptosis (Cyt C, n-
DNA, or fCK-18) elevated (Patient #s 1, 3, 7, 9, 17, and 18) (Table 1).
They were not elevated in patients whose established biomarkers
were all negative (Patients # 12 and 19) (Table 1). These data presented
above, when taken together, suggest that the elevation of serum fortilin
levels accurately predicts apoptosis occurring in vivo and that serum
fortilin levels more sensitively detect in vivo apoptosis than do Cyt C,
n-DNA or fCK-18 levels.
3.5. Serum fortilin levels are drastically elevated in mice with apoptosis-
induced liver damage
To further validate the serum fortilin level as a biomarker of apopto-
sis in vivo, we turned to a mouse model of apoptosis-induced liver
damage in which intraperitoneally administered Armenian hamster
anti-Fas-antigen antibody (Jo2) rapidly and selectively induces Fas-
mediated hepatocyte apoptosis, leading to severe liver damage without
affecting other organs [27]. Since different strains ofmice exhibit a vast-
ly different response to Jo2 antibody [31], we ﬁrst characterized the
liver injury in C57BL/6J mice to which we intraperitoneally adminis-
tered Jo2 antibody (Fig. 5A). Within 3 h of injection, mice became
grossly ill and were dead within 9 h. The livers of mice treated with
Jo2 antibody were hemorrhagic, both grossly and at a microscopic
level, resembling human fulminant hepatitis (Fig. 5B and C–H & E).
TUNEL staining (Fig. 5C-TUNEL, Fig. 5D) showed numerous TUNEL-
positive, apoptotic hepatocytes suggesting that fas-mediated hepato-
cyte apoptosis predominantly resulted in liver damage in the current
system (TUNEL indices: control (CTL) vs. Jo2 = 0.00 ± 0.00 vs.
40.46± 3.46%, n=5, P b 0.005). The vast majority of Jo2 antibody's ef-
fects were on the liver, as the caspase 3 activity of the liver increased
Fig. 1.Development and characterization of fortilin ELISA. Abbreviations: Ab, antibody; HRP, horseradish peroxidase; TMB,3,3′,5,5′-tetramethylbenzidine. A. The design of fortilin ELISA. B.
Detection limits of the fortilin ELISA. Each span of the error bar represents 3 × standard deviation (SD). C. Histogram of mouse serum fortilin levels D. Probability plot of mouse serum
fortilin levels using the normal distribution ﬁt with the 5th and 95th percentile values of 26.84 and 69.48 ng/mL. E. Histogram of human serum fortilin levels. F. Probability plot of
human serum fortilin levels using the gamma distribution ﬁt with 5th and 95th percentile values of 18.68 and 163.55 ng/mL.
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showed only a 6.09-fold increase in caspase-3 activity (P b 0.005, n=
3; Fig. 5E). As expected, the administration of Jo2 antibody resulted in
a drastic increase in the serum alanine transaminase (ALT) levels (con-
trol vs. Jo2 = 39.33 ± 7.02 vs. 272.50 ± 88.39 U/L, n = 3, P b 0.05;
Fig. 5F). Serum n-DNA levels were also elevated in Jo2-treated animalsFig. 2. Serum fortilin levels are increased after anti-cancer therapy (radiation therapy, che-
motherapy, or both). Abbreviations: *, statistically signiﬁcant (P b 0.05); PRE, pre-anti-
cancer therapy; POST, post-anti-cancer therapy. A. Change in serum fortilin levels
[ng/mL] in 18 patients undergoing anti-cancer therapy. The details of the patients are in
Table 1. B. Change in serum fortilin levels when pre-treatment levels were normalized
to one. Patient #10: a sufﬁcient amount of post-treatment sample was available only for
fortilin ELISA, thus included for serum fortilin assay but excluded from the other assays.
Patient #5: excluded from the study as post-treatment sample volume was not sufﬁcient
for any assays.(control vs. Jo2 = 1.00 ± 0.75 vs. 7.64 ± 1.75 A.U., n = 5, P b 0.005;
Fig. 5G). In this system, serum fortilin levels were found to be 2.63-
fold elevated in Jo-2 treated animals vs. their control (86.18 ± 27.71
vs. 226.31 ± 48.51 ng/mL, n= 4, P b 0.005; Fig. 5H). These ﬁndings in
the well-characterized mouse model of apoptosis-induced liver injury
suggest that serum fortilin levels represent a viable marker of in vivo
apoptosis.3.6. Fortilin excretion from the cell precedes the compromise of the plasma
membrane integrity
To evaluate the possibility that the elevation of serum fortilin levels
observed abovewas due solely to the passive release of fortilin from the
damaged cells, we challenged Jurkat cells, a human T lymphocyte cell
line, with anti-human Fas IgM (CH-11, 12.5 ng/mL), harvested aliquots
of cells and conditioned media at times 0, 0.5, 1, 2, 4, and 8 h (Fig. 6A),
and subjected the cells to (a) 7-aminoactinomycin D (7-ADD) staining
to identify cells with plasma membrane damage (Fig. S3) and (b) a
DNA fragmentation assay to monitor the progression of apoptosis. We
also subjected the conditioned media to the assays for n-DNA, Cyt C,
fCK-18, LDH, and fortilin (Fig. 6A). In this system, 7-ADD-positive Jurkat
cells did not signiﬁcantly increase until 4 h after the induction of apo-
ptosis (Fig. 6B). Similarly, the LDH concentration in the media did not
signiﬁcantly increase until 4 h after apoptosis was induced (Fig. 6C).
Taken together, these data suggest that plasma membrane integrity
becomes compromised (PMΔ) between 2 and 4 h after the initiation
of Fas-induced apoptosis in this system. DNA fragmentation within
the cell began right after anti-Fas stimulation, progressed steadily, and
Fig. 3. Infrequent increases in serum lactate dehydrogenase (LDH) levels suggest a lack of extensive necrotic tissue damage in the study patients. Abbreviations: LDH, lactate dehydroge-
nase; *, P b 0.05; PRE, pre-anti-cancer therapy; POST, post-anti-cancer therapy. A. Change in serum LDH levelswhen pre-treatment levelswere normalized to one. B. Serum LDH levels did
not correlate signiﬁcantly with serum fortilin levels.
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fragmentation assays performed on the cell lysates (Fig. 6D), suggesting
that plasma membrane disruption occurring between 2 and 4 h after
apoptosis induction coincided with the very late phase of apoptosis in
this system. Using this system and fortilin ELISAs, we tested whether
fortilin was actively released from apoptosing Jurkat cells before the
plasma membrane disintegrated. Jurkat cells do not secrete fortilin
into the media without apoptotic stimuli (Fig. S4). Strikingly, fortilin
concentrations in the media drastically increased just 30 min after theFig. 4. Known serum markers of apoptosis do not increase as much as fortilin levels upon ant
fragmented cytokeratin-18; *,P b 0.05; PRE, pre-anti-cancer therapy; POST, post-anti-cancer the
ment levels were normalized to one. There was no statistically signiﬁcant association between s
serum nucleosomal DNA (n-DNA) levels when their pre-treatment levels were normalized to
levels by regression analysis (P= 0.18, R2 = 11.9%). C. Changes in serum fragmented cytoke
was no statistically signiﬁcant association between serum fCK-18 and fortilin levels by regressinduction of apoptosis, well before there were any detectable signs of
plasma membrane disintegration (Fig. 6E; 0.5, 1, and 2 h), supporting
the idea that fortilin is actively released from the apoptosing cells via
exosomes [15]. While n-DNA exhibited release kinetics similar to
those of fortilin (Fig. 6G), the concentrations of Cyt C and fCK-18 in
the medium did not increase until 4 h had passed, suggesting that the
release of those apoptosis biomarkers required the change to the plas-
ma membrane (Fig. 6F & H). These data suggest that fortilin is actively
released from apoptosing cells in the very early phase of apoptosisi-cancer therapy. Abbreviations: Cyt C; cytochrome c; n-DNA, nucleosomal DNA; fCK-18,
rapy;Δ, fold change. A. Changes in serumcytochrome c (Cyt C) levelswhen their pre-treat-
erum Cyt C and fortilin levels by regression analysis (P= 0.635, R2 = 1.5%). B. Changes in
one. There was no statistically signiﬁcant association between serum n-DNA and fortilin
ratin-18 (fCK-18) levels when their pre-treatment levels were normalized to one. There
ion analysis (P= 0.082, R2 = 18.8%).
Fig. 5. Serum fortilin levels increase in response to Jo2-antibody-induced apoptosis in the liver. Abbreviations: PBS, phosphate-buffered saline; CTL, control; i.p., intraperitoneal injection;
ALT, alanine aminotransferase; n-DNA, nucleosomal DNA; H&E, hematoxylin and eosin staining; TUNEL, Terminal deoxynucleotidyl transferase dUTP nick-end labeling staining; *,
P b 0.05; **, P b 0.01; ***, P b 0.005. A. C57BL/6J mice were injected with Jo2 antibody and sacriﬁced 5–9 h later. B. The livers of control and Jo2-treated mice. C. Hematoxylin & eosin
(H&E) and TUNEL staining of the control and Jo2-treated livers. Size bar: 100 μm. D. TUNEL index (%) of the control and Jo2-treated livers. E. Caspase-3 activities of control and Jo2-treated
organs. F. Serum alanine aminotransferase (ALT) levels in control and Jo2-treatedmice. G. Serum n-DNA levels in control and Jo2-treatedmice. H. Serum fortilin levels in control and Jo2-
treated mice.
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plasma membrane detectable by the elevation of LDH and traversing
of 7-AAD into the cells.
4. Discussion
There are three innovations in the current work. First, the present
study is the ﬁrst to report the development and characterization of an
ELISA system capable of measuring fortilin in mouse and human sera.
Our fortilin ELISA system both sensitively (detection limit = 0.4 ng/mL)
and reliably (%CV = 8.6%) detected both human and mouse serum
fortilins (Fig. 1). Second, it has been unknown whether fortilin circulates
in the blood of normal subjects. We are the ﬁrst to show that fortilin
circulates in the blood of normal congenic C57BL6/J mice and apparently
healthy humans (Fig. 1). Third, using the ELISA system, we demonstrate
for the ﬁrst time that serum fortilin is a unique biomarker of apoptosis
(Fig. 2), distinct from andmore sensitive and speciﬁc than the previously
reported serum biomarkers of apoptosis [5], including Cyt C, n-DNA, and
fCK-18 (Figs. 4, S5).
Renz and others reported that Cyt C not only translocates from the
mitochondrial intermembrane space into the cytosol, but also is re-
leased into the extracellular space in response to apoptotic stimuli [8].
They found that the serum levels of Cyt C are elevated immediately
after anti-cancer chemotherapy in patients with predominantly hema-
tological malignancies [8]. When serum Cyt C levels were measured
by quantitative Western blot analysis, more than a 2-fold increase in
Cyt C levels was present in 8 out of 17 patients tested (47.1%) [8].
Other groups also reported that serum Cyt C levels are elevated in
patients with un-treated malignant tumors, and that an elevatedserum Cyt C level is an adverse prognostic marker [32–34]. However,
Jemmerson and others reported that Cyt C release could occur from
both apoptotic and necrotic cells [9]. In addition, Osaka and others
found that there was a signiﬁcant and positive correlation between
serum Cyt C and LDH levels [32]. It is not entirely clear whether serum
Cyt C becomes elevated solely and always due to apoptosis in vivo
since, at least theoretically, any cell death stimuli that disrupt both
mitochondria and the plasma membrane would release Cyt C into the
extracellular space. In the current work, we found only 2 patients to
have statistically signiﬁcant elevation of Cyt C levels (Fig. 4A) after
anti-cancer therapy, while 14 (77.8%) out of 18 patients had statistically
signiﬁcant increase in fortilin levels (Fig. 4A). The relative lack of sensi-
tivity of Cyt C, compared to fortilin, could be explained by the results of
Fig. 6, where we found that both Cyt C and fCK-18 require disruption of
the plasmamembrane to be released into the extracellular space (Fig. 6F
& H). On the contrary, fortilin and n-DNA did not require such plasma
membrane changes and were released from the cells in the very early
phase of apoptosis (on and after 0.5 h; Fig. 6E & G), presumably through
exosomes [15] and apoptotic bodies [35], respectively.
n-DNA are produced by the cleavage of chromosomal DNA by endo-
nucleases activated during apoptosis and can be released into the circu-
lation. Holdenrieder and others showed that patients with malignant
tumors had higher levels of serum n-DNA than did healthy subjects
and those with benign tumors and that serum n-DNA levels increased
in response to anti-cancer therapy [36]. Despite the fact that the gener-
ation of n-DNAs is speciﬁc to apoptosis and that they appear to be
released from the cell in an active process via apoptotic bodies [35] in
the early phase of apoptosis (Fig. 6G), the serum n-DNA levels were
found not to be as sensitive as serum fortilin levels in detecting
Fig. 6. Fortilin is released in the very early phase of apoptosis, before the compromise to the plasmamembrane integrity. Abbreviations:α-Fas IgM, anti-human Fas IgM (clone CH11); CM,
conditionedmedia; n-DNA, nucleosomal DNA; 7-AAD, 7-aminoactinomycin D; Cyt C, cytochrome c; fCK-18, fragmented cytokeratin-18; LDH, lactate dehydrogenase; PMΔ, plasmamem-
brane change; *, P b 0.05. A. Experimental design. Jurkat cells were challenged by 12.5 ng/mL of anti-human Fas IgM (clone CH11) in Roswell ParkMemorial Institute (RPMI) media with
5% fetal bovine serum (FBS). Cells and conditioned media were harvested at indicated time points and subjected to the respective sets of assays as described in the panel. 7-AAD cannot
pass through the intact plasmamembrane. 7-AAD cannot enter into the live cell. B. 7-AAD staining to detect cells with change in plasmamembrane integrity. C. LDH concentrations in the
conditionedmedia. D. n-DNA concentration in the cell lysates that reﬂect the progression of apoptosis occurringwithin the cell. E. Fortilin concentrations in the conditionedmedia. F. Cyt C
levels in the conditioned media. G. n-DNA concentration in the conditioned media. H. fCK-18 concentration in the conditioned media.
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only 4 (23.5%) showed a statistically signiﬁcant increase in n-DNA levels
after anti-cancer therapy, while 2 (11.7%) had a statistically signiﬁcant
decrease (Fig. 4B). The apparently low sensitivity of n-DNA in human
samples (Fig. 4B) may at least partly be due to the fact that circulating
n-DNA is rapidly degraded by serum DNases within hours of its release
into the circulation [7].
Cytokeratin-18 (CK-18) is a major component of intermediate
ﬁlaments of epithelial cells and tumors derived from such cells [6].
During apoptosis, caspase-3 cleaves CK-18 into three fragments—NH2-
terminal, 26-kDa; middle, 19-kDa; and COOH-terminal, 3-kDa. The
M30 antibody recognizes a neo-epitope on the middle 19-kDa frag-
ment, exposed only after caspase-3 cleavage of CK-18 [29]. Levels of
the caspase-cleaved, 19-kDa, CK-18 fragment (fCK-18) were reported
to be signiﬁcantly elevated in patients with gastric cancer vs. healthy
subjects [37,38]. fCK-18 levels also increased signiﬁcantly after cancer
chemotherapy [39]. However, it was also reported that both caspase-
cleaved and uncleaved/intact CK-18s are elevated (a) in patients with
cancer compared to healthy subjects [4,38] and (b) after cancer chemo-
therapy [34,40], suggesting that the release of CK-18s relies on the
disruption of the plasma membrane. In addition, CK-18 is present only
in epithelial cells and may not be useful for the detection of apoptosis
in other tissue types such as muscle, connective, and nervous tissues.
In the current work, of 17 samples tested, only 2 (11.7%) showed a
statistically signiﬁcant increase in fCK-18 levels after anti-cancer thera-
py, while one (5.8%) had a statistically signiﬁcant decrease (Fig. 4C),
suggesting that serum fCK-18 levels are not as sensitive as serum fortilin
levels in detecting apoptosis at least in the current cohort of patients
with SCC undergoing anti-cancer therapy.
Fortilin has three key attributes that make it a preferred serum
biomarker of apoptosis. First, it is released in the very early phase of
apoptosis, well before the integrity of the plasma membrane iscompromised (Fig. 6B, C, & E). In other words, fortilin is an authentic
apoptosis marker, and its release into the extracellular space does not re-
quire plasmamembrane damage, unlike Cyt C, fCK-18, and LDH (Fig. 6C, F
& H). Second, it is detected in patients undergoing anti-cancer therapy
more sensitively and consistently than are Cyt C, n-DNA, and fCK-18
(Figs. 2 & 4, Table 1), most likely due to its stability in the blood and its
ability to be secreted from the cell without plasmamembrane disruption.
Third, our clinical study (Figs. 2, 3, & 4), animal experiments (Fig. 5), and
cell-based experiments (Fig. 6) all support fortilin as a serum apoptosis
biomarker (Fig. S5) superior to those previously reported.
In conclusion, our current work for the ﬁrst time establishes serum
fortilin as a viable apoptosis biomarker, which is secreted from
apoptosing cells into the circulation in the very early phase of apoptosis
and detectable by the ELISA. Further translational studies would deﬁne
the precise roles of serum fortilin levels in the diagnosis and treatment
of patients with the medical conditions in which apoptosis plays a key
role.
Supplementary information is available at the website of the BBA
Clinical (http://dx.doi.org/10.1016/j.bbacli.2014.10.002).
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